Selected Start-Ups (7/01)
In Vivo summarizes the technologies of these recently founded companies: Aviva Antibody Corp. will produce monoclonal antibodies for the post-genomics research efforts of future corporate partners. Corus Pharma Inc. will focus on the rapid clinical development and regulatory approval of small-molecule drugs for sleep disorders and respiratory diseases. Isogenica Ltd.'s Covalent Display, is an in vitro library technology for rapidly identifying polypeptides with high affinity and specificity for any given target. Liposonix Inc. will use high-intensity ultrasound to remove unwanted subcutaneous fat. Scienion AG will develop "future-oriented" biochips for use in genomics and proteomics research, DNA diagnostics and the drug discovery and development. Xcellsyz Ltd.'s platform for drug discovery and development is based on conditionally immortalized cell lines that retain many of the properties of primary cells.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.